摘要
目的探讨甲泼尼龙联合孟鲁司特对复发性过敏性紫癜(HSP)患儿血清免疫球蛋白A(IgA)、白细胞介素-6(IL-6)水平的影响。方法选取2017年12月至2019年1月辽健集团阜新矿总医院收治的复发性HSP患儿96例作为研究对象,依照治疗方案不同分为观察组与对照组,各48例。对照组给予孟鲁司特钠治疗,观察组采用甲泼尼龙联合孟鲁司特钠治疗。比较两组疗效、尿常规恢复正常时间、关节肿痛缓解时间、腹痛缓解时间、皮肤紫癜消失时间、住院时间、IgA、IL-6、不良反应发生率、随访6个月复发率。结果观察组治疗有效率为93.75%(45/48),高于对照组77.08%(37/48)(P<0.05);观察组住院时间、尿常规恢复正常时间、关节肿痛缓解时间、腹痛缓解时间、皮肤紫癜消失时间短于对照组(P<0.05);治疗后观察组血清IgA、IL-6水平低于对照组(P<0.05);观察组不良反应发生率12.50%(6/48)与对照组8.33%(4/48)比较,差异无统计学意义(P>0.05);观察组随访6个月复发率2.12%(1/47)低于对照组12.76%(6/47)(P<0.05)。结论甲泼尼龙联合孟鲁司特治疗小儿复发性HSP疗效确切,能改善临床症状及体征,降低血清IgA、IL-6水平,缩短住院时间,降低复发率,安全性高。
Objective To explore the effect of methylprednisolone combined with montelukast on serum immunoglobulin A(IgA)and interleukin-6(IL-6)levels in child patients with recurrent henoch-sehonlein purpura(HSP).Methods A total of ninety-six child patients with recurrent HSP treated in Fuxin Mine General Hospital of Liaojian Group from December 2017 to January 2019 were selected as the research objects and were divided into an observation group(48 cases)and a control group(48 cases)according to different treatment schemes.The control group was treated with montelukast sodium,and the observation group was treated with methylprednisolone+montelukast sodium.The curative effect,the time to return to normal urine routine,the time to relieve joint swelling and pain,the time to relieve abdominal pain,disappearance time of skin purpura,length of hospital stay,serum immunoglobulin A(IgA),interleukin-6(IL-6),incidence of adverse reactions,6-month follow-up recurrence rate were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.75%(45/48),which was higher than the control group of 77.08%(37/48)(P<0.05);the time of hospitalization,time to return to normal urine,time to relieve joint swelling and pain,time to relieve abdominal pain,and disappearance time of skin purpura in the observation group were shorter than those in the control group(P<0.05);after treatment,the serum IgA and IL-6 levels in the observation group were lower than those in the control group(P<0.05);the incidence of adverse reactions in the observation group was 12.50%(6/48)compared with 8.33%(4/48)in the control group,with no significant difference(P>0.05);the recurrence rate in the observation group during the 6-month follow-up was 2.12%(1/47)lower than that in the control group 12.76%(6/47)(P<0.05).Conclusion Methylprednisolone combined with montelukast has a definite curative effect on recurrent HSP in children,which can improve clinical symptoms and signs,reduce serum IgA and IL-6 levels,shorten hospital
作者
王岩
黄雅玲
WANG Yan;HUANG Ya-Ling(Fuxin Mine General Hospital of Liaojian Group,Fuxin 123000,China)
出处
《中国药物经济学》
2020年第8期90-92,96,共4页
China Journal of Pharmaceutical Economics
关键词
过敏性紫癜
甲泼尼龙
孟鲁司特
Henoch-sehonlein purpura
Methylprednisolone
Montelukast
